MedPath

Shionogi, Inc

🇺🇸United States
Ownership
-
Established
1919-01-01
Employees
-
Market Cap
$13.1B
Website
https://www.shionogi.com/jp/ja/

A Clinical Study to Evaluate the Safety of Ospemifene

Phase 3
Completed
Conditions
Atrophy
Vaginal Diseases
Interventions
First Posted Date
2007-12-04
Last Posted Date
2018-05-18
Lead Sponsor
Shionogi
Target Recruit Count
426
Registration Number
NCT00566982

Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions

Phase 3
Completed
Conditions
Mental Retardation
Neurological Conditions
Cerebral Palsy
Sialorrhea
Interventions
First Posted Date
2007-06-26
Last Posted Date
2012-07-09
Lead Sponsor
Shionogi
Target Recruit Count
137
Registration Number
NCT00491894
Locations
🇺🇸

The Children's Center, Bethany, Oklahoma, United States

🇺🇸

Rocky Mountain Pediatrics, Lakewood, Colorado, United States

🇺🇸

Child Neurology Associates, PC, Atlanta, Georgia, United States

and more 4 locations

A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia

Phase 3
Completed
Conditions
Combined Hyperlipidemia
Interventions
First Posted Date
2007-04-12
Last Posted Date
2018-04-24
Lead Sponsor
Shionogi
Target Recruit Count
481
Registration Number
NCT00459745
Locations
🇺🇸

East-West Medical Research Institute, Honolulu, Hawaii, United States

🇺🇸

Welborn Clinic Gateway, Newburgh, Indiana, United States

🇺🇸

Memorial Research Medical Clinic, Long Beach, California, United States

and more 52 locations

A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women

Phase 3
Completed
Conditions
Atrophy
Vaginal Diseases
Interventions
Drug: Ospemifene 30 mg
Drug: Ospemifene 60 mg
Drug: Placebo
Drug: Nonhormonal vaginal lubricant
First Posted Date
2006-01-12
Last Posted Date
2013-06-28
Lead Sponsor
Shionogi
Target Recruit Count
826
Registration Number
NCT00276094

Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer

Phase 1
Completed
Conditions
Non Small Cell Lung Cancer
Lung Cancer
Stage IIIA Non Small Cell Lung Cancer
Stage IIIB Non Small Cell Lung Cancer
Interventions
Drug: S-3304
Other: Chemo-irradiation
First Posted Date
2004-02-26
Last Posted Date
2018-05-02
Lead Sponsor
Shionogi
Target Recruit Count
9
Registration Number
NCT00078390
Locations
🇺🇸

Lombardi Cancer Center, Washington, District of Columbia, United States

🇺🇸

Scripps Cancer Institute, La Jolla, California, United States

🇺🇸

University of Kansas Cancer Center, Kansas City, Kansas, United States

and more 2 locations

A Phase 1 Study of S-3304 in Patients With Solid Tumors

Phase 1
Completed
Conditions
Solid Tumors
First Posted Date
2002-04-10
Last Posted Date
2018-04-26
Lead Sponsor
Shionogi
Target Recruit Count
32
Registration Number
NCT00033215
Locations
🇺🇸

Roswell Park Cancer Center, Buffalo, New York, United States

🇺🇸

H. Lee Moffitt Concer Center and Research Institute, Tampa, Florida, United States

🇺🇸

Cleveland Clinic Foundation, Cleveland, Ohio, United States

and more 1 locations
© Copyright 2025. All Rights Reserved by MedPath